Diabetes

Top Story

Invokana superior to glimepiride for glycemic control, weight loss, BP

May 27, 2016

ORLANDO, Fla. — Over 52 weeks, glycemic control was improved and body weight and blood pressure were reduced with Invokana as add-on therapy to metformin in patients with type 2 diabetes, according to a presentation here.

In the randomized, double blind study, Katherine Merton, PhD, of Janssen Scientific Affairs, and colleagues evaluated data from 1,450 adults (mean age, 56.2 years) with type 2 diabetes (mean HbA1c, 7.8%; mean BMI, 31 kg/m2) on background metformin randomly assigned to Invokana (canagliflozin, Janssen) 100 mg or 300 mg or glimepiride for 52 weeks to determine the effects of the treatments on metabolic syndrome components.

Meeting News Coverage

Neuropathy expert receives AACE Distinction in Endocrinology Award

May 27, 2016
Orlando, Fla. — Aaron I. Vinik, MD, PhD, FCP, MACP, FACE, professor of medicine, pathology and neurobiology and director of the research and neuroendocrine unit…
Meeting News Coverage

Findings clarify between diabetic exocrine pancreatopathy, chronic pancreatitis

May 27, 2016
SAN DIEGO —  A chart review of 16 deceased individuals highlighted differences between diabetic exocrine pancreatopathy and chronic pancreatitis, according to…
Meeting News Coverage

Preparation key to diabetes management during air travel

May 26, 2016
ORLANDO, Fla. — The mismanagement of diabetes during air travel can lead to adverse consequences, including hypoglycemia during eastward travel and hyperglycemia…
CME CNE CPE

The Emerging Biosimilar Therapeutic Landscape: Scientific Foundations and Clinical Implications

This activity is supported by an educational grant from Boehringer-Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Recent processes have been established to facilitate the production, validation, and utilization of biosimilars…
More »
Video
Meeting News Coverage

VIDEO: Concentrated insulins may help with adherence

April 8, 2016
More »
Featured
CME

Avoiding “Loss of Chance”…Improving the Screening, Treatment, and Referral of Patients with Diabetic Retinopathy

This activity is supported by an educational grant from Genentech, Inc.

Despite a number of effective treatment options, diabetic eye disease is a leading cause of vision loss in the United…
More »
Meeting News Coverage

Invokana superior to glimepiride for glycemic control, weight loss, BP

May 27, 2016
ORLANDO, Fla. — Over 52 weeks, glycemic control was improved and body weight and blood pressure were reduced with Invokana as add-on therapy to…

Meeting News Coverage

Neuropathy expert receives AACE Distinction in Endocrinology Award

May 27, 2016
Orlando, Fla. — Aaron I. Vinik, MD, PhD, FCP, MACP, FACE, professor of medicine, pathology and neurobiology and director of the research and…

Meeting News Coverage

Findings clarify between diabetic exocrine pancreatopathy, chronic pancreatitis

May 27, 2016
SAN DIEGO —  A chart review of 16 deceased individuals highlighted differences between diabetic exocrine pancreatopathy and chronic…

Meeting News Coverage

Preparation key to diabetes management during air travel

May 26, 2016
ORLANDO, Fla. — The mismanagement of diabetes during air travel can lead to adverse consequences, including hypoglycemia during eastward travel…

Meeting News Coverage

Inpatient self-management for diabetes effective

May 26, 2016
ORLANDO, Fla. — Inpatients with diabetes may effectively manage their own diabetes and achieve diabetes care equally as effective as standard…

Meeting News Coverage

Addition of Farxiga to insulin, liraglutide improves glycemia in type 1 diabetes

May 26, 2016
ORLANDO, Fla. — Patients with type 1 diabetes treated with insulin and liraglutide with the addition of Farxiga have significantly improvements…

Meeting News Coverage

Liraglutide as adjunct to insulin reduces HbA1c, BMI

May 26, 2016
ORLANDO, Fla. — Patients with type 1 diabetes treated with liraglutide as an adjunct to insulin had significantly reduced HbA1c and BMI…

FDA News

FDA advisory panel recommends approval for Sanofi-Aventis’ iGlarLixi combination drug

May 25, 2016
An FDA advisory panel has recommended approval of Sanofi-Aventis’ new drug application 208673 for insulin glargine and lixisenatide injection…

Meeting News Coverage

AACE/ACE app offers clinical guidance for management of type 2 diabetes

May 25, 2016
ORLANDO, Fla. —The American Association of Clinical Endocrinologists and the American College of Endocrinology announced the worldwide…

FDA News

FDA advisory panel to discuss new drug application for Sanofi’s LixiLan combination drug

May 25, 2016
An FDA advisory panel will meet today to discuss the safety and efficacy of two new drug applications, 208673 for insulin glargine and lixisenatide…

More Headlines »
morganatic-roan